Fujifilm Diosynth Biotechnologies opens new laboratory facility in Research Triangle Park, NC
Construction now complete on new 62,000 square foot facility.
Fujifilm Diosynth Biotechnologies has completed the construction of a new three-story, 62,000 square foot state-of-the-art facility in Research Triangle Park, North Carolina. A ribbon cutting ceremony was held on 9 May 2016. Members of the local government and biotech community were in attendance at the event.
“The construction and completion of this building reflects the continued commitment of our organization to provide our clients with the infrastructure to efficiently and innovatively bring their products to the clinic and beyond for the benefit of their patients,” said Steve Bagshaw, CEO, Fujifilm Diosynth Biotechnologies.
The new building, called BioProcess Innovation Center, houses the company’s Process and Analytical Research and Development, Process Sciences and Stability groups. These will concentrate on delivering excellence in process invention, design and development and process and product characterization for the company's clients. They will also continue to innovate to further develop systems and approaches which rapidly lead to efficient, robust and high quality biomanufacturing processes.
“The design of the facility reflects our core philosophy of cross-functional collaboration to Research and Process Development which is a key differentiator of our company,” said Martin Meeson, President, Fujifilm Diosynth Biotechnologies USA, Inc. “Developer Alexandria Real Estate Equities, Inc., and General Contractor, KBR Building Group, LLC, brought a wealth of experience in life science building projects to this new addition to Fujifilm Diosynth Biotechnologies, located at 6051 George Watts Hill Drive.”
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance